Fineline Cube

Follow:
14422 Articles
RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin
Company

RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin

Xuanzhu Biopharma's XZP-3621 Approved for ALK-Positive NSCLC in China
Others

Xuanzhu Biopharma’s XZP-3621 Approved for ALK-Positive NSCLC in China

Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs
CompanyDeals

Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs

Dizal Pharma Reports 74.4% Revenue Growth in 2025 Semi-Annual Results
Company

Dizal Pharma Reports 74.4% Revenue Growth in 2025 Semi-Annual Results

Daiichi Sankyo's Enhertu Submitted for Priority Review in China for HER2-Positive Breast Cancer
CompanyDrug

Daiichi Sankyo’s Enhertu Submitted for Priority Review in China for HER2-Positive Breast Cancer

DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer
Others

DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer

Yantai Dongcheng's 225Ac-LNC1011 Injection Gains FDA Approval for Prostate Cancer Trial
CompanyDrug

Yantai Dongcheng’s 225Ac-LNC1011 Injection Gains FDA Approval for Prostate Cancer Trial

Ocumension's OT-301 Meets Primary Endpoint in Denali Phase III Trial
CompanyDrug

Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial

Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection
CompanyDrug

Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection

Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
CompanyDeals

Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development

Zhongsheng Pharma's Onradivir Granted Drug Registration in Macau
CompanyDrug

Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau

Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners
CompanyDeals

Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners